Amid a report that the COVID-19 antibody treatment from Regeneron loses its effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology said on Tuesday that their antibody drug is ...
GlaxoSmithKline (GSK-0.81%) has confirmed plans to separate its consumer and pharmaceutical business units. However, an activist investor appears to want the big drugmaker to take more drastic actions ...
The loss of coverage for thousands of Arizonans reliant on the Flovent inhaler was not the result of GlaxoSmithKline ...
GlaxoSmithKline (LSE:GSK), is undergoing a transformation and the company is expected to split into 2 entities mid 2022. Shareholders had an underwhelming performance in the last 3 years, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results